



## ADULT MEDICATION GUIDELINE

# Fosfomycin

<b>Scope (Staff):</b>	All WNHS Staff
<b>Scope (Area):</b>	Obstetrics and Gynaecology

This document should be read in conjunction with the [Disclaimer](#).

## Quick Links

[Dose](#)

[Administration](#)

[Monitoring](#)

[Pregnancy and Breastfeeding](#)

## Restrictions

[Formulary: Restricted](#)

## Medication Class

Bactericidal

## Presentation

**Granules for oral liquid:** 3g (1 sachet)

## Storage

Store at room temperature, below 25°C

## Dose

### Uncomplicated Urinary Tract Infection

*For the treatment of urinary tract infections where resistance to multiple other agents has been proven and pathogen is susceptible to Fosfomycin. See [Formulary One](#).*

#### **Oral:**

3g sachet single dose

### Complicated Urinary Tract Infection

#### **Oral:**

3g sachet every 3 days for 3 doses

## Administration

### Oral

Mix the contents of the sachet in water and drink immediately

Take at bedtime, after emptying bladder

## Monitoring

Urine culture and sensitivity, before and after therapy

## Pregnancy

**1<sup>st</sup> Trimester:** Considered safe to use

**2<sup>nd</sup> Trimester:** Considered safe to use

**3<sup>rd</sup> Trimester:** Considered safe to use

## Breastfeeding

Considered safe to use

## Comments

Sodium bicarbonate, Ural<sup>®</sup> or Citravescent<sup>®</sup> reduce efficacy of fosfomycin when used for urinary tract infections. Avoid taking them on the same day as, or within 2 days after taking fosfomycin.

Not suitable for pyelonephritis as oral administration is unlikely to achieve adequate systemic concentrations.

## Related Policies, Procedures & Guidelines

### **HDWA Policies:**

[Formulary One](#)

### **WNHS Policies:**

[Antimicrobial Stewardship](#) (intranet only)

### **KEMH Clinical Guidelines:**

[Infections: urinary tract infection in pregnant women](#)

### **KEMH Pharmaceutical & Medicines Management Guidelines:**

[Medication Administration](#) (intranet only)

## References

Therapeutic Guidelines. Acute cystitis in adults. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2019 [cited 2023 May 16]. Available from: <https://tgldcdp.tg.org.au>

Truven Health Analytics. Fosfomycin Tromethamine. In: Micromedex [Internet]. Greenwood Village (CO): Truven Health Analytics; 2023 [cited 2023 May 16]. Available from: <http://www.micromedexsolutions.com/>

Australian Medicines Handbook. Fosfomycin. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2023 [cited 2023 May 16]. Available from: <https://amhonline.amh.net.au/>

Seroy JT, Grim SA, Reid GE, Wellington T, Clark NM. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis. *J Antimicrob Chemother.* 2016;71(9):2563-2568. doi:10.1093/jac/dkw178

Matthews PC, Barrett LK, Warren S, et al. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. *BMC Infect Dis.* 2016;16(1):556. Published 2016 Oct 11. doi:10.1186/s12879-016-1888-1

Briggs GC, Freeman RK. Fosfomycin. In: *Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk* [Internet]. 11 th ed. Lippincott Williams & Wilkins; 2023 [cited 2023 May 16].

APILAM: association for promotion and cultural and scientific research of breastfeeding. Fosfomycin. *E-lactancia* [Internet]. 2002 [updated 2022 Aug 3; cited 2023 May 16]. Available from: <http://www.e-lactancia.org/breastfeeding/fosfomycin/product/>

Keywords	Fosfomycin, UTI, urinary tract infection, multi resistant UTI, resistant urinary tract infection				
Document Owner:	Chief Pharmacist				
Author/Reviewer	KEMH Pharmacy Department				
Version Info:	4.0				
Date First Issued:	01/2018	Last Reviewed:	16/05/2023	Review Date:	16/05/2026
Endorsed by:	Medicines and Therapeutics Committee			Date:	01/08/2023
NSQHS Standards Applicable:	<input checked="" type="checkbox"/>  Std 1: Clinical Governance <input type="checkbox"/>  Std 2: Partnering with Consumers <input checked="" type="checkbox"/>  Std 3: Preventing and Controlling Healthcare Associated Infection <input checked="" type="checkbox"/>  Std 4: Medication Safety		<input type="checkbox"/>  Std 5: Comprehensive Care <input type="checkbox"/>  Std 6: Communicating for Safety <input type="checkbox"/>  Std 7: Blood Management <input type="checkbox"/>  Std 8: Recognising and Responding to Acute Deterioration		
<b>Printed or personally saved electronic copies of this document are considered uncontrolled.          Access the current version from WNHS HealthPoint.</b>					

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.